Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab versus zoledronic acid for low bone mineral density in women with spinal cord injury
MOH_2020-12-20_008974Phase 4Not yet recruiting
- Sponsor
- ד"ר ליאנה טריפטו שקולניק
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in low bone mineral density comparing Romosozumab arm with Zoledronic acid arm (2 arms). Primary endpoints: Change in bone mineral density, Change in bone formation markers and 1 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
romosozumabzoledronic acid
03
Conditions
low bone mineral density
Beyond the preview
Go deeper on MOH_2020-12-20_008974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-20_008974.